Diabetic Nephropathy – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs intended to halt the progression of kidney damage associated with diabetes. In June 2019, detailed results of the CREDENCE trial of Johnson & Johnson’s Invokana (canagliflozin) were published. By demonstrating a significant reduction in the relative risk of a renal-specific composite endpoint, Invokana became the first antidiabetic drug to demonstrate a renoprotective effect in a dedicated renal outcomes trial. The SGLT-2 inhibitor has opened the door for this drug class to be used to lower eGFR limits, potentially shifting treatment patterns in this market.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed DN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DN patients?
- How have Invokana and other SGLT-2 inhibitors been integrated into the treatment algorithm, and what is their source of business?
- What percentage of DN patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of DN patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
CONTENT HIGHLIGHTS
Markets covered: United States.
Key companies: Eli Lilly, AstraZeneca, Johnson & Johnson, Pfizer, Novo Nordisk.
Key drugs: Jardiance, Farxiga, Invokana, Steglatro, Novolog.
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Table of contents
- Diabetic Nephropathy - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA | Diabetic Nephropathy | US | July 2021
- Treatment Algorithms CDA | Diabetic Nephropathy | US 2021 Dashboard
Dwaipayan Chatterjee, M.Pharm., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. He has authored reports focusing on metabolic and cardiovascular indications. Previously, he was an equity analyst for the U.S. healthcare sector with Market Realist, where he worked on competitive intelligence and analysis of financial data. He was also a market research analyst for Mordor Intelligence, where he gained experience in market sizing, forecasting, and analyzing market dynamics. He holds a master’s degree with a specialization in pharmaceutical chemistry from the Birla Institute of Technology & Science in Pilani, India.